Abivax is a French clinical-stage biotech company developing oral therapies for chronic inflammatory diseases, with ulcerative colitis as a lead focus. Its pipeline centers on novel anti-inflammatory mechanisms rather than marketed products, which explains limited current revenue. The company works primarily with investigators, trial sites and future specialty-care markets in gastroenterology and inflammation.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 0 | — | -52.4 | — |
| Q2 2025 | 0 | — | -48.4 | — |
| Q3 2025 | 0 | — | -153.4 | — |
| Q4 2025 | 0 | — | -82 | — |
| Q1 2026 | 0 | — | -48.5 | — |
All markets — KeepWinning global stock screener
Other companies on Euronext Paris: Itissalat Al-Maghrib (IAM) S.A. (IAM), Gaztransport & Technigaz SA (GTT), SPIE SA (SPIE), Edenred SE (EDEN), Compagnie du Cambodge (CBDG), Nexans S.A. (NEX)